Literature DB >> 10772705

Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94).

J H Chan1, S D Chamberlain, K K Biron, M G Davis, R J Harvey, D W Selleseth, R E Dornsife, E H Dark, L W Frick, L B Townsend, J C Drach, G W Koszalka.   

Abstract

A series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94) were synthesized and evaluated for activity against human cytomegalovirus (HCMV) and for cytotoxicity. The 2-substituents in the benzimidazole moiety correspond to those that were used in the 1263W94 series. In general, as was found in the 1263W94 series, cyclic and branched alkylamino groups were needed for potent activity against HCMV. Three analogues 3a, 3b and 3d were as potent as 1263W94. Further evaluation of two analogues, 3a and 3b, suggested that these 2'-deoxy analogues may act via a novel mechanism of action similar to that of 1263W94. These 2'-deoxy analogues generally lacked cytotoxicity in vitro. Pharmacokinetic parameters in mice and protein binding properties of 3a were quite similar to 1263W94. However, the oral bioavailability of 3a was only half of that observed for 1263W94.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772705     DOI: 10.1080/15257770008032999

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  3 in total

1.  Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Authors:  Karen K Biron; Robert J Harvey; Stanley C Chamberlain; Steven S Good; Albert A Smith; Michelle G Davis; Christine L Talarico; Wayne H Miller; Robert Ferris; Ronna E Dornsife; Sylvia C Stanat; John C Drach; Leroy B Townsend; George W Koszalka
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

2.  Antiviral Drugs Against Herpesviruses.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects.

Authors:  Laurene H Wang; Richard W Peck; Yin Yin; Jane Allanson; Rebecca Wiggs; Mary Beth Wire
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.